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Recruitment started in 1985 and continued until 2004. The initial participation rate was 78.0%. The participants were repeatedly followed up. 9, 10 From May 2005 until May 2010, we mailed an invitation letter to 1208 former participants for a follow-up examination. However, 153 were unavailable because they had died earlier (n=26), because they had been institutionalized or were too ill (n=27), or because they had moved out of the area (n=100). Of the remaining 1055 former participants, 828 renewed informed consent. The participation rate was therefore 78.5%. We excluded 37 participants from analysis because urine samples for urinary proteomics were unavailable (n=22) or because they were lost to follow-up (n=15). Thus, the outcome cohort included 791 participants (for details, see Figure S1 in the online-only Data Supplement).
Assessment of Outcome
At annual intervals, we ascertained vital status through 6 October 2014 via the Belgian Population Registry in Brussels, Belgium. We obtained the International Classification of Disease codes for the immediate and underlying causes of death from the Flemish Registry of Death Certificates. For all 791 participants, we collected information on the incidence of nonfatal events either via a follow-up visit at the examination center with repeat administration of the same standardized questionnaire as used at baseline (n=637) or via a structured telephone interview (n=119).
Coronary events included sudden death, myocardial infarction, acute coronary syndrome, new-onset angina pectoris, ischemic cardiomyopathy, and coronary revascularization. Cardiac events additionally included heart failure, pulmonary heart disease, new-onset atrial fibrillation, life-threatening arrhythmias, and high-degree atrioventricular block requiring pacemaker implantation. Cardiovascular events comprised cardiac end points, stroke, transient ischemic attack, aortic aneurysm, arterial embolism, and revascularization of peripheral arteries. To assess the symptoms associated with heart failure, we administered the London School of Hygiene questionnaires on cardiovascular and respiratory symptoms and dyspnea. Physicians ascertained the diseases reported on the death certificates or by the questionnaires and interviews against the medical records of general practitioners or hospitals. For all end points within a category, we censored participants from analysis after the occurrence of the first event.
Urinary Proteomics
To assess the urinary proteome-based HF1 classifier, 24-h urine samples were processed and analyzed using capillary electrophoresis coupled with mass spectrometry as described previously. 11 The online-only Data Supplement (pages 2-3) gives detailed information on the preparation and processing of the urine samples. The data (on abundance) of the predefined urinary peptide biomarkers were combined into a single summary variable, using the support-vector machine-based MosaCluster software, version 1.7.0. In the present study, we used the previously published multidimensional classifier HF1, which is associated with decreased left ventricular function and which combines information from 85 peptide fragments identified in 19 patients with diastolic LV dysfunction and 19 controls. 6 How support-vector machine modeling establishes the HF1 classifier is described in the onlineonly Data Supplement (pages [3] [4] . In addition, the online-only Data Supplement provides information on the peptides making up HF1 (Table S1 ) and sequenced peptides with known amino-acid sequence (Table S2 ).
Other Measurements
Blood pressure was the average of 5 consecutive auscultatory readings obtained according to European guidelines with a standard mercury sphygmomanometer with the participant in the seated position for at least 10 minutes. As described elsewhere, we applied a stringent quality control program to the blood pressure measurements, looking for digit and number preference. 12, 13 Hypertension was a blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or use of antihypertensive drugs. Body mass index was weight in kilograms divided by height in meters squared. Venous blood samples were drawn for measurement of plasma glucose and serum total and highdensity lipoprotein cholesterol, creatinine, and γ-glutamyltransferase (index of alcohol intake). Glomerular filtration rate was derived by the Chronic Kidney Disease Epidemiology Collaboration equation. 14 Diabetes mellitus was a self-reported diagnosis, a condition mentioned on the death certificate or in records held by general practitioners or hospitals, antidiabetic drug intake, a fasting plasma glucose level of at least 126 mg/dL, or a random blood glucose of at least 200 mg/dL.
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Statistical Analysis
For database management and statistical analysis, we used the SAS system, version 9.3 (SAS Institute Inc., Cary, NC). Means were compared using the large-sample z-test or ANOVA and proportions by Fisher exact test. Statistical significance was a 2-sided significance level of 0.05.
In exploratory analyses, we plotted incidence rates by tertiles of the urinary biomarker, while standardizing for sex and age group (<40 years; 40-60 years; >60 years) by the direct method. In categorical analyses with adjustments applied for sex and age, we plotted the cumulative incidence of cardiovascular and cardiac endpoints by thirds of the HF1 distribution. We used Cox regression to compute standardized hazard ratios, which for continuous variables express the risk associated with a 1-standard deviation (SD) increment in the urinary biomarker. All models accounted for clustering of failure times within pedigrees by fitting a shared frailty model. We checked the proportional hazard assumption using the Kolmogorov-type supremum test. The baseline characteristics considered as covariables in Cox regression were sex, age, body mass index, systolic blood pressure, fasting plasma glucose, serum creatinine, the total-to-high-density lipoprotein cholesterol ratio, γ-glutamyltransferase (as index of alcohol intake), smoking, history of cardiovascular disease, and treatment with diuretics (thiazides, loop diuretics, and aldosterone antagonists), β-blockers, inhibitors of the renin-angiotensin system (angiotensin-converting enzyme inhibitors or angiotensin type-1 receptor blockers), vasodilators (calcium channel blockers or α-blockers), or other antihypertensive drugs. We identified covariables to be retained in the analyses by a step-down procedure, removing the least significant covariable at each step until all P values of covariables were <0.15. We applied the generalized R 2 statistic to assess the contribution of HF1 and systolic blood pressure to risk over and beyond other risk factors. We calculated the multivariable-adjusted 5-year absolute risk of a cardiovascular or cardiac event across thirds of the distributions of HF1 and systolic blood pressure.
Finally, we determined optimal discrimination limits for HF1 by maximizing Younden's index (the maximum of sensitivity plus specificity minus 1). We then assessed the added prognostic accuracy of the optimized thresholds, using the integrated discrimination improvement (IDI) and the continuous net reclassification improvement (NRI). 16 IDI is the difference between the discrimination slopes of the basic model and the basic model extended with HF1. The discrimination slope is the difference in predicted probabilities (%) between subjects with and without end point. To calculate NRI, 16 we predicted in each subject the 5-year risk for an event from a Cox model with and without HF1. If P (up/event) is the percentage of subjects with events whose predicted probability is increased by adding HF1 to the model and if P (up/nonevent) is the percentage of subjects without events whose predicted probability is increased, then NRI equals 2×[P (up/event) -P (up/ nonevent) ]. Table 1 lists the characteristics of participants by thirds of the HF1 distribution (median; −1.03; IQR, -1.60 to -0.44). Age, body mass index, central obesity, blood pressure, serum creatinine, blood glucose and γ-glutamyltransferase, and the total-to-high-density lipoprotein cholesterol ratio all (P≤0.002) increased with higher HF1 category, whereas estimated glomerular filtration rate decreased (P<0.0001). The prevalence of hypertension, being treated for hypertension, having a history 
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Risk Associated with HF1 Categories
Crude rates of cardiovascular, cardiac, and coronary events increased across thirds of the HF1 distribution (Table S4 ; P≤0.0032) with a similar trend for all-cause mortality (P=0.057). The incidence of fatal combined with nonfatal cardiovascular (P=0.014) and cardiac (P=0.009) end points, standardized for sex and age group, increased across thirds of the HF1 distribution (Figure 1 ), whereas the trends for all-cause mortality and coronary events did not reach significance (P≥0.10). For cardiovascular (P=0.046) and cardiac (P=0.028) events, the cumulative incidence ran a significantly higher course in the top compared with the low third of the HF1 distribution ( Figure 2 ). These estimates were standardized to the means of the distributions of sex and age in the whole study population. Based on these results, the risk of cardiovascular and cardiac events was carried forward in multivariable-adjusted analyses.
Multivariable-Adjusted Risk Associated with the HF1 Biomarker
The step-down selection procedure identified sex, age, fasting blood sugar, smoking, and treatment with vasodilators as significant covariables of the risk of a cardiovascular or cardiac event (Table S5) . Table 2 shows the multivariable-adjusted hazard ratios associated with a 1-SD increment in HF1. All Cox models complied with the proportional hazards assumption (P≥0.056). In all 791 participants, HF1 was a significant predictor of fatal and nonfatal cardiovascular (P=0.029) and cardiac events (P=0.018), whereas systolic blood pressure was not (P=0.85 and P=0.66, respectively). The generalized R 2 statistics for entering HF1 or systolic blood pressure (Table 2) as predictor in these models were 0.59 versus 0.01 for cardiovascular events and 0.69 versus 0.03 for cardiac events. Sensitivity analyses, from which we excluded 71 participants with previous cardiovascular disease ( Table 2) , or in all 791 participants with hypertension forced into the Cox models as additional covariable (P values for HF1, ≤0.042; data not shown) were confirmatory. Figure 3 shows the 5-year absolute risk of a cardiovascular or cardiac event in relation to systolic blood pressure ( Figure 3A and 3B) at different levels of HF1 or in relation to HF1 ( Figure 3C and 3D) at different levels of systolic blood pressure. The analyses were standardized to the average of the distributions in the whole study population (mean or ratio) of sex, age, fasting plasma glucose, smoking, and treatment with vasodilators. Figure 3 illustrates that HF1, being significantly related to outcomes (P≤0.033), was more informative than systolic pressure (P≥0.54) in predicting cardiovascular and cardiac events over a 5-year span.
Improvement of Prognostic Accuracy
By maximizing Younden's index (Table 3) , we determined optimal thresholds for HF1 in predicting cardiovascular or cardiac events. Sensitivity of the optimized thresholds ranged from 59% to 86% for cardiovascular events and from 53% to 58% for cardiac events. Specificity ranged from 46% to 75% and from 80% to 81%, respectively. In all 791 participants (Table 4) , both IDI and NRI reached significance for cardiovascular and cardiac events (P≤0.006). In 720 participants free of cardiovascular disease at entry (Table 4) , IDI and NRI were significant for cardiovascular events (P<0.0001) and reached borderline significance for cardiac events (P≤0.086).
Discussion
The key findings of our study were as follows: (i) over a follow-up period of ≈5 years, the multidimensional urinary classifier HF1 predicted the incidence of fatal and nonfatal cardiovascular and cardiac events; (ii) after optimizing the HF1 thresholds, adding HF1 to Cox models, including baseline cardiovascular risk factors, significantly improved prognostic accuracy; (iii) HF1 was more informative than systolic blood pressure in the short-term prediction of cardiovascular and cardiac events. Our current findings are in line with a previous publication showing that in the same cohort, the early diastolic peak velocity of the mitral annulus (e′) predicted the incidence of fatal combined with nonfatal cardiovascular events over a 5-year follow-up period. 17 Over a similar follow-up, mild and moderate-to-severe diastolic left ventricular dysfunction predicted all-cause mortality in the Olmsted County study with hazard ratios amounting to 8.3 and 10.2, respectively (P<0.001). 18 As previously demonstrated in case-control 6 and proof-of-concept 7 studies, HF1 associates with diastolic left ventricular dysfunction.
Under physiological conditions, ≈70% of the urinary protein content originates from the kidney and the urinary tract, whereas the remaining 30% is derived from plasma. 19 We hypothesized that the latter fraction may be informative on cardiac and cardiovascular disease. The multidimensional urinary classifier HF1 combines information on 85 urinary peptides, 6 mainly upregulated and downregulated collagen fragments (Table S2) . Patients with left ventricular dysfunction are characterized by a disturbed balance between collagen synthesis and degradation in the extracellular matrix of the myocardium and an increased interstitial deposition and cross-linking of type I collagen. 20 The cardiac extracellular matrix is predominantly composed of fibrillar collagen type I (85%) and type III (11%). Furthermore, small amounts of collagen types IV and V codistribute with collagen I. The prime location of collagen V is at the fibril core and is important in nucleating collagen I-containing fibrils. 21 The HF1 classifier also includes a downregulated peptide derived from the WW domain-binding protein 11 (Table S2 ) that remained statistically significant after adjustment for multiple testing. 6 WBP11 is an inhibitor of protein phosphatase-1. 22 In cardiomyocytes, protein phosphatase-1 plays a key role in calcium handling and relaxation via dephosphorylation of phospholamban. 23 In patients with heart failure, the activity of protein phosphatase-1 is enhanced, thereby delaying left ventricular relaxation. In line with this pathophysiological pathway, incident heart failure represented 33.3% and 46.7% of the cardiovascular and cardiac events, respectively. We also considered whether reducing the multidimensionality of classifiers, such as HF1, might be possible without losing information. However, we previously demonstrated that a higher number of peptides resulted in higher accuracy by reducing variability in the assessment of single components. 24 In an additional analysis of the current data, we therefore tested a classifier based only on the 3 peptide biomarkers remaining significant after adjustment for multiple testing. 6 As expected, this abridged classifier performed inferior to HF1 in diagnosing diastolic left ventricular dysfunction 7 and in the prediction of cardiovascular and cardiac events (data not shown).
In population studies with long-term follow-up, blood pressure is the main driver of cardiovascular risk. 25, 26 In our current study, HF1 largely outperformed systolic blood pressure in the prediction of cardiovascular and cardiac complications. These observations cannot be attributed to the quality of our blood pressure measurements, as exemplified by the absence of terminal digit and number preference. Several investigators have reported that single blood pressure measurements predicted the risk of cardiovascular disease over a follow-up The optimal discrimination limit was obtained by maximizing Younden's index (the maximum of sensitivity plus specificity minus 1). Hazard ratios (95% confidence interval) present the risk associated with exceeding the biomarker threshold. The hazard ratios were significant (P≤0.0003). Five-year absolute risk of cardiovascular and cardiac events in relation to systolic blood pressure (A, B) at different categories of HF1 and in relation to HF1 (C, D) at different levels of systolic blood pressure. The analyses were standardized to the average of the distributions in the whole study population (mean or ratio) of sex, age, fasting plasma glucose, smoking, treatment with vasodilators (calcium-channel blockers or α-blockers). In panels A and B, the risk functions span the 5th to 95th percentile interval of systolic blood pressure and correspond to the low, medium, and high categories of HF1. In panels C and D, the risk functions span the 5th to 95th percentile intervals of HF1 and correspond to the low (<33th percentile), medium (33-66th percentile), and high (>66th percentile) categories of systolic blood pressure. P values are for the independent effect of HF1 (P HF1 ) and systolic blood pressure (p SBP ). n P and n e indicate the number of participants at risk and the number of events.
by guest on April 20, 2017 http://hyper.ahajournals.org/ Downloaded from period of 15 to 50 years, but also that the impact of blood pressure diminished with increasing duration of follow-up. [27] [28] [29] [30] [31] [32] [33] [34] The strongest evidence in this regards comes from the Framingham Heart Study. 34 Vasan and coworkers used sex-and age-specific multivariable Cox regression to evaluate the association of current blood pressure (at baseline), recent antecedent blood pressure (average of readings for all available examinations 1-10 years before baseline), and remote antecedent blood pressure (average for all available examinations 11-20 years before baseline) with the 10-year risk of new-onset cardiovascular disease in 2313 Framingham Study participants. During follow-up, cardiovascular disease occurred in 899 participants. In multivariable-adjusted models, recent and remote antecedent blood pressure predicted the risk of cardiovascular disease incrementally over current blood pressure. This observation was consistent in multiple subgroups: women (n=1403) and men (n=910) and 3 age strata (60-69, 70-79, and ≥80 years). 34 Explanations offered by the Framingham investigators were that antecedent blood pressure is a forerunner of cardiovascular target organ damage, which is on the path to hard cardiovascular complications, and that the relation between cardiovascular risk and blood pressure might be weakened by the initiation of antihypertensive drug treatment. 34 Our current findings remained consistent after exclusion of participants with a history of cardiovascular disease. Similarly, estimates of the hazard ratios remained confirmatory if we forced hypertension as covariable in the Cox models or if we limited the analyses to participants untreated for hypertension at baseline (data not shown).
Use of vasodilators, calcium-channel blockers or α-blockers, at baseline was among the significant predictors of cardiovascular or cardiac events, for which our analyses were adjusted. Although resulting from an observational study, our findings are not surprising in view of the results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [35] [36] [37] In ALLHAT, use of doxazosin or amlodipine, compared with chlorthalidone was associated with an increased risk of combined cardiovascular disease. This secondary end point was driven by congestive heart failure 35-37 and coronary revascularization, 35-37 and for doxazosin also by hospitalized or treated angina pectoris.
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Diuretics, β-blockers, angiotensin-converting enzyme inhibitors, and angiotensin type-1 receptor blockers are drug classes used in the primary and secondary prevention of cardiovascular complications, in particular heart failure, but in our current study, use of these drug classes at baseline did not predict cardiovascular or cardiac complications. To our knowledge, there is no other population-based study that explored the value of the urinary proteome in predicting cardiovascular or cardiac complications. Nevertheless, our study must be interpreted within the context of its limitations. First, the sample size and number of events were substantially smaller than, for instance, in the Framingham Heart Study. 34 This might explain why we could not show any significant prognostic value of HF1 in relation to the incidence of mortality or coronary events. Second, our current study with a median follow-up of 6.1 years does not allow to compare the prognostic value of HF1 and blood pressure over a longer follow-up. Third, we did not assess the incremental predictive value of HF1 with other biomarkers of risk, such as high-sensitivity C-reactive protein 38 or high-sensitivity troponin T.
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Perspectives
Our current study demonstrated that the urinary proteome, but not systolic pressure, predicts incident cardiovascular and cardiac disease over a 5-year period and thereby confirmed the diagnostic utility of the urinary proteomic signature. [6] [7] [8] Further prospective studies should underpin its use in clinical practice compared with other biomarkers over varying intervals of follow-up in relation to different end points. A previous publication in the same cohort demonstrated that the early diastolic peak velocity of the mitral annulus (e′) predicts the incidence of fatal combined with nonfatal cardiovascular events over a 5-year follow-up period. 17 When we introduced both HF1 and e′ in multivariable-adjusted models (62 cardiovascular and 44 cardiac events in 776 participants who underwent an assessment of their diastolic left ventricular function; data not shown), both were predictive, albeit with borderline P values (0.020≤P≤0.097), reflecting complementarity of information. The basic reference models included as covariables sex, age, fasting plasma glucose, smoking, and treatment with vasodilators. The IDI is the difference between the discrimination slopes of basic models and basic models extended with HF1. The discrimination slope is the difference in predicted probabilities (%) between cases and controls. Controls are participants without incident cardiovascular or cardiac disease. The NRI is the sum of the net percentages of subjects reclassified correctly in cases and controls. CI indicates confidence interval; IDI, integrated discrimination improvement; and NRI, net reclassification improvement.
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However, for screening purposes, HF1 is less costly and labor-intensive than echocardiography and therefore preferable. Having the urinary proteome confirmed as a short-term predictor of adverse outcomes might allow the timely initiation of preventive or therapeutic measures. On the other hand, quality-of-life of patients confronted with a prognostically adverse urinary proteomic signature and cost-effectiveness remain issues of concern.
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The What Is New?
• In a previous cross-sectional study, we identified a multidimensional urinary peptide-based classifier (HF1), which was associated with left ventricular dysfunction. In randomly recruited Flemish people, we investigated whether HF1 predicts cardiovascular end points over and beyond traditional risk factors.
What Is Relevant?
• Over a 5 year follow-up period, the standardized and multivariable-adjusted hazard ratios relating cardiovascular (n=63) and cardiac (n=45) events with HF1 were 1.30 and 1.39 (P≤0.029), respectively, whereas those with systolic pressure were around unity (P≥0.66).
• The diagnostic improvement obtained by adding optimized HF1 thresholds to Cox models including classical cardiovascular risk factors, including systolic blood pressure, was significant (P≤0.006).
Summary
Over ≈5 years of follow-up, the urinary proteome, but not systolic pressure, predicted incident cardiovascular disease. Further prospective studies should confirm its diagnostic utility compared with other biomarkers over varying intervals of follow-up in relation to different end points. Having the urinary proteome confirmed as a short-term predictor of adverse outcomes might allow the timely initiation of preventive or therapeutic measures.
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Supplement to The Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General
Expanded Methods
Urinary Proteomics
Aliquots of urine were stored at -80 °C. Urine (0.7 mL) was thawed immediately before analysis and diluted with 0.7 mL of 2 M urea, 10 mM NH 4 OH containing 0.02% SDS. 1 To remove higher molecular mass proteins, such as albumin and immunoglobulin G, the samples were ultrafiltered using Centrisart ultracentrifugation devices (20 kDa MWCO;
Sartorius, Göttingen, Germany) at 2,000 g relative centrifugal force until 1. shortly before capillary electrophoresis coupled with mass spectrometry (CE-MS).
As described in detail elsewhere, 2 CE-MS analyses were performed using a P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Brea, CA) on-line coupled to a micrOTOF MS (Bruker Daltonic, Bremen, Germany). The ESI sprayer (Agilent Technologies, Palo Alto, CA) was grounded, and the ion spray interface potential was set between -4 and -4.5 kV. Data acquisition and mass spectrometry acquisition methods were automatically controlled by the capillary electrophoresis via contact-close-relays. Spectra were accumulated every 3 seconds, over a range of charge states (m/z) 350 to 3000.
Previous publications described the accuracy, precision, selectivity, sensitivity, reproducibility, and stability of the CE-MS measurements in detail. 2, 3 Mass spectra were processed using MosaiquesVisu software, including peak picking, deconvolution and deisotoping. 4 Migration time and peak intensity were normalized using internal peptide standards. 5 These fragments result from normal biological processes and Page 3 of 17 appear to be unaffected by any disease state studied to date based on over 20,000 samples in the Mosaiques database. 6 The resulting list of peaks characterizes each peptide by its molecular mass, normalized capillary electrophoresis migration time, and normalized signal intensity. All detected peptides were deposited, matched, and annotated in a Microsoft SQL database, allowing further analysis and comparison of multiple patient groups. Peptide fragments were combined into a single summary variable, using the support-vector machine based MosaCluster software, version 1.6.5.
In the present study, we used the previously published multidimensional classifier, which is associated with decreased left ventricular function and which combines information from 85 peptide fragments identified in 19 patients with diastolic LV dysfunction and 19 controls. parameters. SVMs are frequently implemented in data mining software. In particular, the kernlab cran R package is a versatile tool for building SVM based-classifiers. ID, peptide identifier (SQL number); %, percentage of samples, in which the peptide could be detected; MA, mean signal amplitude of the peptides. R was calculated as ∑ (ln signal amplitude x frequency/number of participants) in controls divided by ∑ (ln signal amplitude x frequency/number of participants) in cases. The peptides were ordered by ascending R.
Reproduced from reference 7. For age and fasting plasma glucose, hazard ratios express the risk per 1-SD increase in the explanatory variable. Models accounted for clustering of failure times within pedigrees. The baseline characteristics considered as potential covariables were sex, age, body mass index, systolic blood pressure, fasting plasma glucose, the total-to-HDL cholesterol ratio, -glutamyltransferase (as index of alcohol intake), smoking, history of cardiovascular disease, and treatment with diuretics (thiazides, loop diuretics and aldosterone antagonists), -blockers, inhibitors of the renin-angiotensin system (angiotensinconverting-enzyme inhibitors or angiotensin type-1 receptor blockers), vasodilators (calcium-channel blockers or -blockers), or other antihypertensive drugs. Covariables to be retained in the analysis were identified by a step-down procedure, removing the least significant covariable at each step until all P-values of covariables were less than 0.15. 
